Treatment with intensive insulin regimens is part of our routine clinical practice for all hospitalized patients with T2D but an important proportion of these patients could be highly exposed to suffer hypoglycaemia [11,24,25,26], which would significantly impact in our clinical practice [27,28,29]. The gene discussed is INS; the disease is Hypoglycemia.